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Abstract The clinical use of doxorubicin (DOX) is limited
by its dose-dependent cardiotoxicity. The present study
investigated the effects of scutellarin against DOX-induced
cardiotoxicity in rats using pharmacodynamic and phar-
macokinetic approaches. DOX (20 mg/kg) was injected
intraperitoneally (i.p.) as a single dose, and scutellarin
(5 mg/kg/day) was injected intravenously (i.v.) for 3 days.
Rats treated with DOX showed acute cardiotoxicity as
indicated by the elevated serum lactate dehydrogenase
(LDH) activity (4057.8 ± 107.2 vs. 2032.7 ± 70.95), tis-
sue malondialdehyde (MDA) level (2.083 ± 0.10 vs.
1.103 ± 0.09), cardiac troponin T (cTnT) concentration
(0.1695 ± 0.0114 ng/mL), the decreased left ventricular
ejection fraction (LVEF) (47.75 ± 15.79 vs. 78.72 ± 7.25)
and left ventricular fractional shortening (LVFS)
(20.66 ± 8.06 vs. 43.7 ± 6.76) compared with those of the
control group. Cotreatment with scutellarin significantly
decreased the LDH activity (2595.9 ± 72.73), MDA level
(1.380 ± 0.06), cTnT concentration (0.0222 ± 0.0041 ng/
m L), increased LVEF (76.70 ± 3.91) and LVFS
(40.28 ± 3.68). Histopathological studies showed disrup-
tion of cardiac tissues in the DOX groups. Cotreatment
with scutellarin reduced the damage to cardiac tissues. In
the pharmacokinetic and tissue distribution study, scutel-
larin reduced the heart tissue exposure to DOX but did not
change the AUC of plasma. These results suggest that
scutellarin can protect against DOX-induced acute
cardiotoxicity through its antioxidant activity and alter-
ations of heart concentrations.
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Introduction
Doxorubicin (DOX) is an effective antineoplastic agent
that is used to treat a wide spectrum of human malignancies
and remains one of the most commonly prescribed drugs
(Pautier et al. 2015; Tap et al. 2016). However, its clinical
usage is limited by the development of severe dose-de-
pendent acute and chronic cardiomyopathy (Manalo et al.
1975; Carvalho et al. 2014), which is usually refractory to
common medications. Approximately 10% of patients
treated with DOX will develop cardiomyopathy (Lipshultz
et al. 2010).The pathogenic mechanisms responsible for
DOX-induced cardiotoxicity have not been completely
elucidated. It is widely accepted that DOX-induced
oxidative stress plays an important role in the pathogenesis
of DOX cardiotoxicity (Guenancia et al. 2015; Guo et al.
2016; Szwed et al. 2016). The quinone moiety of DOX
participates in oxidation–reduction processes and promotes
ROS generation through an enzymatic mechanism that
utilizes the mitochondrial respiratory chain and non-enzy-
matic pathways that incorporate iron (Minotti et al. 2004).
Furthermore, cardiomyocytes exhibit low levels of
antioxidases, such as catalase and superoxide dismutase,
and the antioxidant seledium-dependent-reduced GSH
peroxidase-1 is readily inactivated after DOX exposure. It
has been shown that DOX has a high affinity for cardiolipin
and forms a very stable complex, resulting in DOX accu-
mulation in the heart and aggravation of the heart burden
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(Moulin et al. 2015; Aryal and Rao 2016). DOX-induced
cardiotoxicity could be attenuated by reducing heart
exposure to DOX, such as with liposome-encapsulated
DOX (Batist et al. 2001).
Because DOX is such an effective chemotherapeutic, a
variety of approaches have been evaluated to reduce its
cardiotoxicity, including DOX analogues, alternative drug-
delivery methods, and an iron-chelating agent. One method
of attenuating the risk of DOX-induced cardiotoxicity and
exploiting the full therapeutic potential of DOX is a car-
dioprotective agent that does not affect its antitumor
activity.
Several recent studies have proposed flavonoids, a group
of potent cardioprotective agents, to protect against DOX-
induced cardiotoxicity. Scutellarin (SCU, 4,5,6-trihydrox-
yflavone-7-glucuronide) is a natural flavonoid and the
primary active ingredient of Erigeron breviscapus (vant.)
Hand-Mazz, a Chinese herbal medicine. Its preparations
for injection are widely used in the clinic for the treatment
of cerebral insufficiency and peripheral circulation prob-
lems in China. Many studies have demonstrated that
scutellarin is an effective radical scavenger in vitro and
in vivo. Scutellarin could attenuate H2O2-induced oxida-
tive stress and lipid peroxidation (Liu et al. 2003; Hong and
Liu 2004). In addition, recent studies have suggested that
scutellarin exerts a cardioprotective effect against infarc-
tion and ischemia–reperfusion injury (Lin et al. 2007).The
radical scavenging and anti-oxidation properties of flavo-
noids might be beneficial to decrease DOX-induced car-
diotoxicity. Furthermore, scutellarin was shown to be
effective in the treatment of cardiovascular diseases, and it
is commonly used for dilating blood vessels, improving
coronary flow, and protecting cardiac microvascular
endothelial cells (Liu et al. 2005; Chen et al. 2006; Tang
et al. 2015). Based on the potential role of scutellarin in
ameliorating oxidative stress and injury, this study aimed to
investigate the beneficial effect of scutellarin against DOX-




The reference standard of doxorubicin was purchased from
the China Pharmaceutical Biological Products Analysis
Institute (Shanghai, China). Doxorubicin hydrochloride
was purchased as a powder for injection from Shenzhen
Main Luck Pharmaceuticals Inc. (Shenzhen, China).
Scutellarin (purity[98%) was purchased as a powder from
Shanghai Winherb Medical Science Co. Ltd (Shanghai,
China). MDA, LDH, and Coomassie brilliant blue kits
were purchased from the Nanjing Jiancheng Bio-engi-
neering Institute (Nanjing, China). All solvents used in the
extraction and HPLC analyses of DOX were HPLC grade
and were purchased from Tedia (Tedia, USA).
Animals
All procedures involving animals and their care in this
study were approved by the animal care committee of our
institution in accordance with institutional requirements
and Chinese government guidelines for animal experi-
ments. Male Sprague–Dawley rats (200–250 g weight)
were purchased from Sino-British Sippr/BK Lab Animal
Ltd. (Shanghai, China). The rats were maintained in
pathogen-free conditions with a constant temperature
(24 ± 2 C) and humidity (relative humidity of
55 ± 15%) and a 12-h light/dark cycle. They had free
access to water and identical standard food (when permit-
ted) for all subjects, and the experiments were started after
1 week of acclimation.
Experimental protocol
Experiment 1
Thirty-two rats, fasted overnight before the experiments,
were randomly divided into four groups (n = 8 in each
group) and treated as follows: the control group received a
single i.p. injection of saline on day 1; the SCU group
received 5 mg/kg/day i.v. scutellarin via the tail vein on
day 1, day 2 and day 3; the DOX group received a single
i.p. dose of 20 mg/kg DOX on day 1, followed immedi-
ately by i.v. saline via the tail vein on day 1, day 2 and day
3; the SCU ? DOX group received a single i.p. dose of
20 mg/kg DOX on day 1, followed immediately by i.v.
5 mg/kg scutellarin via the tail vein on day 1, day 2 and
day 3.The dose and injection regimens for DOX were
based on published previously reports (Riad et al. 2009).
On the 4th day, the animals were anesthetized by amo-
barbital. Then, transthoracic echocardiography was per-
formed on anesthetized animals. Blood samples were
collected from the abdominal aorta, and the serum was
separated. The hearts were rapidly excised after sacrifice,
thoroughly washed with cold saline, and then cut into two
parts. The left ventricular wall was fixed in 10% formalin
for histological examination. The other part of the heart
tissue was stored at -20 C until analysis in the lipid
peroxide assay.
Experiment 2
Sixteen rats, fasted overnight before the experiments, were
randomly assigned to the DOX group (n = 8) or
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DOX ? SCU group (n = 8). The DOX group was given
an i.v. single dose of 5.0 mg/kg DOX via the tail vein. The
DOX ? SCU group was given an i.v. single dose of
5.0 mg/kg DOX and a single dose of 5.0 mg/kg scutellarin
5 min after the bolus of DOX via a tail vein. The right
external jugular vein was cannulated for sample collection,
and 0.5 mL blood samples were collected into heparinized
tubes from the jugular vein and withdrawn at 5 min, 0.5, 1,
2, 3, 4, 6, 8, 10, 24, 32, 48, and 72 h after administration.
The plasma was isolated by centrifugation and stored at
-20 C until analysis. At 72 h after the blood collection,
the rats were sacrificed, and the hearts were rapidly
excised. The hearts were thoroughly washed with cold
saline and stored at -20 C until analysis.
Experiment 3
Sixty rats, fasted overnight before the experiments, were
randomly assigned to the DOX group (n = 30) or
DOX ? SCU group (n = 30). The DOX group was given
an i.v. single dose of 5.0 mg/kg DOX via the tail vein. The
DOX ? SCU group was given an i.v. single dose of
5.0 mg/kg DOX and a single dose of 5.0 mg/kg scutellarin
5 min after the bolus of DOX via a tail vein. Six rats from
the DOX group and DOX ? SCU group were euthanized
at 1, 4, 24, 48, and 72 h after DOX administration. Samples
of the heart, liver, spleen, lung, kidney, gut, and muscle
were excised, and they were then washed thoroughly with
cold saline and stored at -20 C until analysis.
Assay of lipid peroxide level
The concentration of free MDA in the heart, a product
formed due to cell membrane peroxidation, was assessed
using an MDA kit according to the manufacturer’s
instructions. In brief, the assay was based on the reaction of
MDA with thiobarbituric acid (TBA), forming stable thio-
barbituric acid-reactive substances (TBARS) that absorb at
532 nm. The lipid peroxide level was expressed as nmol of
MDA per mg protein.
Assay of lactate dehydrogenase (LDH) activity
The LDH activity in serum was estimated using a LDH kit
according to the manufacturer’s instructions by a UV–Vis
spectrophotometer.
Determination of protein content
The protein content of serum and cardiac tissue homo-
genates was determined by a Coomassie brilliant blue kit
according to the manufacturer’s instructions with a UV–
Vis spectrophotometer.
Concentration of cardiac troponin T (cTnT) in blood
serum
The concentrations of cTnT in the serum were determined
by a chemiluminescence immunoassay (Roche Elecsys
2010). The assay was performed in each group, and the
results are expressed as ng/ml.
Echocardiographic assessment of cardiac
physiological alterations
Transthoracic echocardiography (Siemens Sequoir 512)
was performed on anesthetized animals with a linear array
8–12 MHz transducer on the 4th day. M-mold images were
acquired and used for the calculation of LV function using
calculation procedures. Left ventricular ejection fraction
(LVEF) is calculated from end-diastolic volume (EDV)
and end-systolic volume (ESV), using the following for-
mula: LVEF = (EDV - ESV)/EDV. EDV and ESV were
estimated by the Teichholtz method. Left ventricular
fractional shortening (LVFS) is calculated from the dif-
ference of M-mold derived end-diastolic diameter and end-
systolic diameter divided by end-diastolic diameter.
Histopathological studies
The left ventricular walls of heart tissues were fixed in 10%
formalin, routinely processed, and embedded in paraffin.
Sections were cut at 3–5 lm thickness and stained with
hematoxylin and eosin (H&E) for histological examination.
The sections were then viewed under a light microscope. A
histomorphological evaluation of all the heart sections was
carried out by a pathologist who was blinded to the treat-
ment groups.
High performance liquid chromatography (HPLC)
analysis of DOX in plasma and tissues
The DOX concentration in plasma and tissues was ana-
lyzed using HPLC with fluorometric detection. The tissue
samples were homogenized in ten times the volume of ice-
cold saline. Briefly, 20 lL internal standard (20 lg/mL
pirarubicin) and 200 lL of alcohol were added to a 200lL
aliquot of plasma or homogenate, followed by vortexing
for 0.5 min. This mixture was extracted with 600 lL of
dichloromethane. The organic phase (600 lL) was sepa-
rated, evaporated to dryness, reconstituted with methanol,
and injected into the HPLC. The Agilent 1100 HPLC
Series system was equipped with ChemStation software, a
1100-well plate autosampler, online degasser, and a fluo-
rescence detector. Separation was achieved on a C18
reverse-phase column at 30 C using acetonitrile and
0.01 M monopotassium phosphate (pH 4.5) delivered via a
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programmed flow. Fluorometric detection wavelengths
were 237 nm (excitation) and 550 nm (emission).
Statistical analysis
All data are expressed as the mean ± SD. Differences
between the mean values of multiple groups were analyzed
by one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test. The differences between two groups
were analyzed using a two-sided Student’s t test. Statistical
significance was considered at P\ 0.05.
Results
Effect of scutellarin on DOX-induced changes
of MDA levels and LDH activity
Rats treated with a single dose of DOX (20 mg/kg) showed
significantly elevated plasma LDH activity (4057.8 ± 107.20
vs. 2032.7 ± 70.95, P\0.01) andMDA levels (2.083 ± 0.10
vs. 1.103 ± 0.09,P\0.01) comparedwith thoseof the control
group (Table 1). The co-administration of scutellarin with
DOX resulted in a significant decrease in LDH activity
(2595.9 ± 72.73, P\0.01) and MDA levels (1.380 ± 0.06,
P\0.01) compared with those of the DOX group.
Effects of scutellarin on the serum concentration
of cTnT
Cardiac troponins are regulatory proteins of the thin actin
filaments of cardiac muscle. cTnT is a highly sensitive and
specific marker of myocardial injury. In this study, the
cTnT concentration was below the level of detection in the
control and SCU groups (\0.01 ng/mL), indicating there
was no myocardial injury (Fig. 1). The results showed that
3 days after DOX administration, the average cTnT con-
centration in the serum of the DOX group was
0.1695 ± 0.0114 ng/mL, which was significantly elevated
compared with the control group (P\ 0.01). However,
upon co-administration with scutellarin for 3 days, the
concentration of cTnT in the DOX ? SCU group
decreased to 0.0222 ± 0.0041 ng/mL (compared with the
DOX group, P\ 0.01).
Echocardiographic assessment of cardiac
physiological alterations
Left ventricular function was similar between the control
group and the SCU group (Fig. 2). At day 3, significant
compromises in LVEF were observed in the DOX-treated
group compared with the control group (47.75 ± 15.79 vs.
78.72 ± 7.25, P\ 0.01). The LVEF of the DOX ? SCU
group was close to the level of the control group and higher
than that of the DOX-treated group (76.70 ± 3.91,
P\ 0.05). The LVFS was also significantly lower in the
DOX-treated group than that in the control group
(20.66 ± 8.06 vs. 43.7 ± 6.76, P\ 0.01). The LVFS was
improved in the DOX ? SCU group compared with that of
the DOX-treated group (40.28 ± 3.68, P\ 0.01).
Morphological changes of the myocardium
In the histopathological examinations, both the control and
SCU-treated groups revealed normal heart histology
(Fig. 3a, h). The DOX-treated group showed severe cardiac
damage. Myocardial fibrosis (indicated by a white arrow),
myocardial degeneration and necrosis, inflammatory cell
infiltration (indicated by a white star), and occasional
vacuolization (indicated by a black arrow) were observed
in this group (Fig. 3b–e). However, in the DOX ? SCU
group, light microscopy investigation revealed slight car-
diac damage. Occasional myocardial degeneration and
inflammatory cell infiltration were detected, although there
was no evidence of fibrosis (Fig. 3f, g).
Effects of scutellarin on the changes
of pharmacokinetic and tissue distribution of DOX
HPLC was used to quantify the DOX concentration in
plasma and tissues. We studied the effect of scutellarin on
DOX pharmacokinetics and tissue distribution within 72 h.
Table 1 Effect of scutellarin on DOX-induced changes in MDA
levels and LDH activity
Group MDA (n moles/mg protein) LDH (U/L)
Control 1.103 ± 0.09 2032.7 ± 70.95
DOX 2.083 ± 0.10** 4057.8 ± 107.2**
DOX ? SCU 1.380 ± 0.06* 2595.9 ± 72.73*
SCU 1.126 ± 0.12 2054.3 ± 40.4
Values are expressed as the mean ± SD (n = 8)
* Compared with the DOX-treated group, P\ 0.01
** Compared with the control group, P\ 0.01
Fig. 1 Effect of DOX and/or scutellarin on the concentration of cTn
T in serum. **Compared with DOX-treated group, P\ 0.01
X.-P. Sun et al.
123
The 72 h time-point was selected based on data from
pharmacokinetic studies showing that the average terminal
half-life of DOX was between 12 and 48 h and because
acute cardiotoxicity appears between 48 and 72 h (Iqbal
et al. 2008; Todorova et al. 2010). The mean plasma
concentration–time curve of DOX is presented in Fig. 4,
and the major pharmacokinetic parameters are summarized
in Table 2. There were no significant differences in the
main pharmacokinetic parameters between the DOX-trea-
ted group and the DOX ? SCU group. The concentrations
of DOX in primary tissues in the tissue distribution are
summarized in Table 3. Excluding the heart, there were no
significant differences between the two groups for most
tissues. The DOX concentration in the heart of the
DOX ? SCU group was lower than that in the DOX-
treated group, and there were significant differences at 1,
48 and 72 h (P\ 0.05) (Fig. 5). These results show that
scutellarin can reduce heart tissue exposure to DOX
without changing the AUC of plasma.
Discussion
Dose-dependent cardiotoxicity and congestive heart failure
remain major limitations in standard and high dose
anthracycline chemotherapy, strongly affecting the survival
of cancer patients. DOX-induced cardiotoxicity in patients
has been subdivided into acute and chronic forms,
depending on the occurrence following administration
(Outomuro et al. 2007). The cause of DOX-induced acute
cardiotoxicity appears to be multifactorial, although most
studies support the theory that enhanced oxidative stress
and antioxidant deficits play significant roles in DOX-in-
duced acute cardiomyopathy and congestive heart failure
(Zhou et al. 2001; Takemura and Fujiwara 2007). Fur-
thermore, cardiocytes have poor antioxidant defense sys-
tems compared with other normal tissues. DOX could
disturb the antioxidant defense systems and repair path-
ways (Nikitovic et al. 2014), aggravating the oxidative
damage to the heart. Many antioxidants, such as a-to-
cophenol, ascorbic acid, reduced glutathione, probucol,
carvedilol, and others, can protect against DOX-induced
acute cardiotoxicity (Yoda et al. 1986; Geetha et al. 1990;
Shimpo et al. 1991; Santos et al. 2002; El-Demerdash et al.
2003), although their efficacies are different and clinical
results have been disappointing.
Currently, much attention has been paid to the use of
phytochemicals as a protective strategy against DOX-in-
duced cardiotoxicity. Flavonoids are a group of polyphenol
compounds that exhibit numerous pharmacological prop-
erties that are beneficial for human health (Havsteen 2002).
Partly due to their radical-scavenging, antioxidative, and
iron-chelating properties, flavonoids are considered
potential protectors against cardiotoxicity caused by DOX
(Kaiserova et al. 2007) or could improve the therapeutic
index of DOX (Du et al. 2009).These flavonoids remain in
the experimental stage because of their low solubility and
oral bioavailability, however, scutellarin widely used for
clinical treatment of cerebral insufficiency and peripheral
circulation problems in China.
Scutellarin is a polyphenolic flavonoid compound and
shows high free radical-scavenging activity, is a highly
effective antioxidant and protects cells from oxidative
stress. The present study demonstrated that scutellarin
could protect against DOX-induced cardiotoxicity and
oxidative injury. Rats treated with DOX showed car-
diotoxicity as indicated by elevated LDH activity, tissue
MDA level and cTnT concentration, and decreased LVEF
and LVFS. Cotreatment with scutellarin significantly
decreased the LDH activity, MDA level and cTnT con-
centration, and increased LVEF and LVFS. Histopatho-
logical studies showed disruption of cardiac tissues in the
DOX groups. Cotreatment with scutellarin could reverse
the damage to the cardiac tissues. These results demon-
strate that scutllarin’s antioxidative effect may underlie the
protection against DOX cardiotoxicity.
Another important factor that could mediate cardiotox-
icity is high affinity binding of DOX to cardiolipin, an
anionic phospholipid in the inner mitochondrial membrane,
which has been proposed as a privileged target (Moulin
et al. 2015). The cardiotoxicity of DOX is related to the
dose intensity and, to a certain extent, to the peak and
Fig. 2 Effects of DOX alone or
combined with scutellarin on
LVEF and LVFS of rats.
*Compared with DOX-treated
group, P\ 0.05; **compared
with DOX-treated group,
P\ 0.01
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cumulative concentrations in heart tissue. Studies in ani-
mals and human clinical trials have demonstrated that the
tissue distribution of DOX is known to be schedule-
dependent. The reduced cardiotoxicity of conventional or
pegylated liposome encapsulated DOX is related to the
decreased concentration of DOX in the heart.
Fig. 3 Histopathological examination of rat heart (H&E). Control group (a) and SCU-treated group (h) showed normal morphology. DOX-
treated group shows myocardial fibrosis, myocardial degeneration and necrosis, inflammatory cell infiltration and occasional vacuolization (b–e).
However, only occasional myocardial degeneration and inflammatory cell infiltration was detected in DOX ? SCU group (f and g). (white arrow
means myocardial fibrosis; white star means myocardial degeneration and necrosis, inflammatory cell infiltration; black arrow means occasional
vacuolization)
X.-P. Sun et al.
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In the pharmacokinetic and tissue distribution study,
scutellarin significantly reduced the concentration of DOX in
heart tissues. However, scutellarin did not change the plasma
pharmacokinetic parameters, such as the AUC, Cmax, and
T1/2. Flavonoids are the substrates of some transporters and
metabolic enzymes, and a number of studies have investi-
gated the effect of flavonoids on the transport of DOX in
tumors and on the metabolism of DOX. These studies indi-
cated that flavonoid-P-gp or MRPs could occur in vivo,
resulting in pharmacokinetic interactions (Morris and Zhang
Fig. 4 Mean plasma concentration–time curve of DOX along after
single dose of 5 mg/kg along or in combination with 5 mg/kg of
scutellarin (n = 8)
Table 2 Major pharmacokinetic parameters of single i.v dose of
5 mg/kg DOX alone or in combination with 5 mg/kg of scutellarin
(n = 8)
Parameter DOX group DOX ? SCU group
AUC(0–t)/ng/L*h 1871.42 ± 261.07 1839.58 ± 281.93
AUC(0–?)/ng/L*h 2100.16 ± 389.68 2028.48 ± 374.27
Cmax/ng/L 1244.64 ± 271.36 1118.63 ± 154.74
Tmax/h 0.0833 0.0833
t1/2z/h 25.36 ± 7.61 24.12 ± 6.67
CLz/L/h/kg 1465.76 ± 271.47 1514.50 ± 258.69


















DOX 40.98 ± 3.12 8.47 ± 0.50 7.12 ± 0.84 9.73 ± 1.24 12.70 ± 1.77 14.84 ± 1.64 3.01 ± 0.09 5.22 ± 0.30
DOX ? SCU 41.37 ± 2.79 7.63 ± 0.46** 5.60 ± 0.69 8.05 ± 0.20 14.06 ± 1.18 13.24 ± 1.40 2.84 ± 0.50 4.91 ± 0.54
4 h
DOX 36.89 ± 8.66 6.43 ± 1.07 4.24 ± 0.79 11.99 ± 2.31 9.68 ± 1.89 10.86 ± 1.81 3.59 ± 0.41 4.68 ± 1.07
DOX ? SCU 21.24 ± 1.97 5.48 ± 0.72 2.69 ± 0.43 9.33 ± 1.21 9.34 ± 0.97 9.62 ± 0.87 3.34 ± 0.67 4.25 ± 0.55
24 h
DOX 16.61 ± 2.42 2.57 ± 0.82 1.15 ± 0.23 8.69 ± 0.94 6.44 ± 1.59 5.70 ± 0.64 2.50 ± 0.72 3.48 ± 0.59
DOX ? SCU 14.40 ± 3.54 3.04 ± 0.39 1.22 ± 0.33 8.34 ± 1.69 7.16 ± 0.31 5.72 ± 0.60 2.20 ± 0.25 3.63 ± 0.54
48 h
DOX 6.93 ± 1.13 1.67 ± 0.10 1.11 ± 0.13 10.24 ± 0.58 5.29 ± 0.33 3.03 ± 0.18 0.99 ± 0.09 2.48 ± 0.20
DOX ? SCU 5.99 ± 1.46 1.03 ± 0.12** 0.87 ± 0.14 9.68 ± 0.87 4.12 ± 0.27 2.61 ± 0.41 0.89 ± 0.12 1.76 ± 0.28**
72 h
DOX 4.22 ± 0.54 0.94 ± 0.07 0.76 ± 0.06 9.79 ± 0.83 4.08 ± 0.30 1.91 ± 0.16 0.75 ± 0.04 1.29 ± 0.15
DOX ? SCU 3.27 ± 0.89 0.69 ± 0.12** 0.68 ± 0.13 8.57 ± 1.43 3.63 ± 0.64 1.74 ± 0.35 0.65 ± 0.10 1.21 ± 0.11
Values are expressed as the mean ± S.D. (n = 6)
** Compared with the DOX-treated group, P\ 0.01
Fig. 5 Mean heart concentration–time curve of DOX along after a
single dose of 5 mg/kg along or in combination with 5 mg/kg of
scutellarin. (n = 6). **Compared with DOX-treated group, P\ 0.01
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2006). Luteolin and quercetin were reported to regulate
transporters, sensitizing tumor cells to DOX (Du et al.
2008, 2009). The cardiotoxicity of anthracyclines has been
attributed to the intramyocardial formation of C-13 alcohol
metabolites (Mordente et al. 2003). Quercetin has better
cardioprotective effects against DOX cardiotoxicity, and it
could significantly inhibit the metabolic conversion of DOX
to doxorubicinol (Vaclavikova et al. 2008). The aldo–keto
reductase inhibitors phenobarbital and rutin also could alter
the metabolism, pharmacokinetics, and toxicity of anthra-
cycline (Behnia andBoroujerdi 1999;Kang andWeiss 2003).
However, it has not been reported that flavonoids can
diminish heart exposure to DOX. Working et al. (1999)
reported that DOX-mediated cardiotoxicity is most directly
related to the peak plasma and/or tissue concentrations of the
drug, although antitumor activity is more closely related to
the plasmaAUC.According to this conclusion, it is beneficial
for cardioprotection that scutellarin reduce DOX accumula-
tion in the heart. Otherwise, the antitumor activity might not
be reduced because the AUC of plasma does not change.
Recently, Todorova et al. found that glutamine supplemen-
tation resulted in a significant reduction of DOX concentra-
tion in heart tissues, without a significant effect on tumor
DOX concentration (Todorova et al. 2010), although this
study did not elucidate the mechanism. The reason for
reduced accumulation of DOX in the heart might be that
scutellarin competes with a specific transport protein char-
acterized by saturable uptake or active specific efflux-protein,
such as multidrug resistance-associated protein (MRP) 2 and
organic anion-transporting polypeptide (OATP) 2B1 (Cou-
ture et al. 2006;Gao et al. 2012), promotingDOXefflux in the
heart. In addition, disruption of DOX-cardiolipin complexes
might also result in decreased concentrations of DOX in the
heart.
Our study demonstrates for the first time that scutellarin
can protect against DOX-induced acute cardiotoxicity
through its antioxidant activity and can influence heart
accumulation. Scutellarin decreases DOX accumulation in
the heart without changing the pharmacokinetics of plasma.
Further studies are needed to elucidate the molecular
mechanism of scutellarin on cardioprotection of DOX
within the heart.
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